clinical trial · NCT06782477
A Study of STAR-0310 in Healthy Adult Participants
Astria Therapeutics, Inc.·phase1·active not recruiting·n = 40
Healthy ParticipantsSTAR-0310Placebo
brief summary
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.
started
Jan 7, 2025
primary completion
Jan 1, 2026
completion
Jan 1, 2026
last updated
Nov 4, 2025
official title
A First-in-Human, Phase 1a, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STAR-0310 in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol